ClinicalTrials.gg

Glomerulosclerosis, Focal Segmental clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 106 studies for Glomerulosclerosis, Focal Segmental across more than 10 countries. 34 are recruiting or about to start. 60 of them are mainly about Glomerulosclerosis, Focal Segmental (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
50
Recruiting
31
Terminated
10
Withdrawn
4
Active, not recruiting
4
Status unknown
4

Phase

Phase 2
37
Phase 1
16
Phase 3
11
Phase 4
5
Early Phase 1
1

Where

United States
69
Italy
13
United Kingdom
13
Canada
12
China
12
France
12

Who develops what

Add Glomerulosclerosis, Focal Segmental to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 6 companies, 3 with this as their studies’ main aim; 2 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Akebia Therapeutics, Bio-Thera Solutions and Boehringer Ingelheim here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
apecotrep☆ Track1 live phase-3 study: NCT07220083Boehringer Ingelheim

The 1 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Mar 2027 est.sparsentan · Travere Therapeutics, Inc. · Phase 4 named, not the main aimNCT07219121 Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis — primary endpoint: Urinary protein/creatinine ratio (UPCR) · 20 enrolled
  • 12 Mar 2027 est.sparsentan · Travere Therapeutics, Inc. · Phase 2 main aimNCT05003986 Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases — primary endpoint: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of interest (AEOIs) · 67 enrolled
  • Jun 2027 est.praliciguat · Akebia Therapeutics · Phase 2 main aimNCT07268638 A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) — primary endpoint: Change from Baseline in urine protein-to-creatinine ratio (UPCR) (Part A) · 60 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Glomerulosclerosis, Focal Segmental studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Angiotensin receptor blockers (ARBs) 1 open · Endothelin receptor antagonists 1 open · Corticosteroids 5 · Calcineurin inhibitors 3

Coming up

11studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger. 23 (74%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (6%) take healthy volunteers.

Recruiting studies that take each age, of 31
AgeWomenMen
1019 (61%)19 (61%)
1828 (90%)28 (90%)
3024 (77%)24 (77%)
4024 (77%)24 (77%)
5023 (74%)23 (74%)
6523 (74%)23 (74%)
7523 (74%)23 (74%)
8514 (45%)14 (45%)

Across all 106 studies, recruiting or not: 46% stop at 75 or younger and 31% at 65; 53% take children; 0% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Glomerulosclerosis, Focal Segmental studies take

Of 17 phase 2 interventional studies under Glomerulosclerosis, Focal Segmental, half reached primary completion within 35 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 235 mo21–42 · 17 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 106. Browse all 106 → or search them.